Soleno Therapeutics Faces Class Action Over DCCR Safety Concerns

Written by Emily J. Thompson, Senior Investment Analyst

Source: PRnewswire

Updated: Mar 07 2026

0mins

Source: PRnewswire

Soleno Therapeutics Inc. has seen its stock price drop by 7.68%, hitting a 5-day low amid ongoing legal troubles.

A securities class action lawsuit has been filed against Soleno, alleging that the company downplayed significant safety risks associated with its DCCR drug (VYKAT™ XR) during clinical trials. This lawsuit follows a previous report that caused a 26% drop in stock price, raising concerns about the drug's commercial viability and investor confidence. The lawsuit claims that these actions have led to substantial investor losses and could have serious implications for the company's future.

The ongoing legal challenges highlight the potential financial repercussions for Soleno and the erosion of market confidence in its products. Investors are urged to stay informed about the developments in this case as it may affect the company's stock performance.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Let AI Trade for You

Auto Trading Task on NVDA?

Get Started Free